{"id":"W4283315989","doi":"10.1097/01.hs9.0000843712.33707.fe","title":"S205: ZANUBRUTINIB + OBINUTUZUMAB (ZO) VS OBINUTUZUMAB (O) MONOTHERAPY IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PRIMARY ANALYSIS OF THE PHASE 2 RANDOMIZED ROSEWOOD TRIAL","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Clinical endpoint; Obinutuzumab; Internal medicine; Gastroenterology; Phases of clinical research; Follicular lymphoma; Progression-free survival; Refractory (planetary science); Randomized controlled trial; Surrogate endpoint; Surgery; Oncology; Clinical trial; Lymphoma; Chemotherapy; CD20","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001666372,0.0005438222,0.00266232,0.0004495527,0.0002891668,0.0000351453,0.0007170135,0.0002372914,0.003465971],"category_scores_gemma":[0.0005912743,0.0003338135,0.001097413,0.003737339,0.0004182926,0.0001532522,0.0003620324,0.0006213324,0.00001065],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.04146889,"about_ca_system_score_gemma":0.02278767,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001725557,"about_ca_topic_score_gemma":0.0002492023,"domain_scores_codex":[0.9928858,0.001349917,0.001511131,0.0009386852,0.002503069,0.0008113678],"domain_scores_gemma":[0.9959366,0.0008617371,0.0008074063,0.001888964,0.0002600897,0.0002452557],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9821133,0.003173914,0.0003938275,0.000192069,0.003788944,0.0002853685,0.001565035,0.001351316,0.0002497782,0.00007837463,0.001171901,0.005636168],"study_design_scores_gemma":[0.9731329,0.004865267,0.0008420288,0.000147162,0.0023226,0.00003865577,0.0005036517,0.01281359,0.000633326,0.00002697226,0.004273592,0.0004002666],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9908827,0.0007654286,0.00004270852,0.0001225247,0.0002962784,0.005708543,0.0001006531,0.00008055955,0.002000613],"genre_scores_gemma":[0.9937873,0.0001261449,0.0002924975,0.0005482446,0.0001046263,0.001098925,0.0003237233,0.0001269829,0.003591517],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01868122,"threshold_uncertainty_score":0.9999114,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01326491986349082,"score_gpt":0.2789006242860502,"score_spread":0.2656357044225593,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}